Lv1
30 积分 2024-02-25 加入
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
1个月前
已完结
Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
1个月前
已完结
Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
1个月前
已完结
The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
2个月前
已完结
Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study
2个月前
已完结
Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma
2个月前
已完结
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
2个月前
已完结
Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries
2个月前
已完结
On-target Effects of GLP-1 Receptor Agonists on Thyroid C-cells in Rats and Mice
2个月前
已完结
Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis
2个月前
已完结
皖公网安备34019202002308
